Stock Market Cafe
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Stock Market Cafe
No Result
View All Result
Home Trading News

Investing Club: We’re increasing our price target on a club health stock

by
January 5, 2022
in Trading News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

The second-half is ‘not looking good’: Strategists on how to weather the market storm

Tesla Pauses Plants After Ending Shaky Quarter With a Production Milestone

Joseph Papa, CEO, Bausch Health
Scott Mlyn | CNBC

(This article was sent first to members of the CNBC Investing Club with Jim Cramer. To get the real-time updates in your inbox, subscribe here.)

We are raising our price target on shares of Bausch Health (BHC) to $36, up from $29 previously, ahead of the company’s presentation at the annual J.P. Morgan Healthcare Conference on Jan. 12 — the most newsworthy healthcare conference of the year. At the event, we expect to hear positive updates on the company’s strategic initiatives — most notably, the upcoming (date not yet announced, though expected early this year) IPO spinoff of Solta Medical. Recall, Solta is the company’s rapidly growing (32% compounded annual sales growth rate or “CAGR” from 2017 to 2020) leading global medical aesthetics business.

As a reminder, when we initiated the position we used a sum of the parts (SOTP) analysis and applied a 22.4x adjusted EBITDA multiple on Bausch + Lomb, in line with Swiss peer Alcon and a conservative 2.6x multiple on the remaining Bausch Pharma business due to it being the most challenged aspect of the company.

Additionally, we used a 30x adjusted EBITDA multiple on our 2021 EBITDA estimate of $171.5 million, which we noted was on the lower end given that peers the Beauty Health Co (SKIN) and InMode traded at ~73x and 30x forward adjusted EBITDA expectations at the time of the alert.

Loading chart…

With the Solta IPO expected shortly and the potential for further clarity on the timeline to be provided at next week’s conference, we believe investor focus on this sum of the parts view will increase and that shares will benefit as a result. We therefore want to update and revise our model as it relates to Solta. We will leave the other two segments unchanged for now.

Given that we have now entered 2022, and expect increased clarity on the Solta IPO in the coming days to weeks, we want to roll forward our EBITDA numbers to FY2022. However, regarding the appropriate growth rate used to generate our estimate, we believe we were too conservative the first time around when we applied a 27% rate (the top line growth rate) to EBITDA, which compounded at 87% from 2017 to 2020.

Of course, that 87% benefits greatly from a small starting base, so, we must account for that. In FY2020, adjusted EBITDA grew 55% YoY, down from 81% in FY2019 and 140% in FY2018. If we assume a 40% rate in 2021 followed by a 35% rate in 2022, our FY2021 estimate goes from $171.5 million to $189 million while our FY2022 estimate comes in at $255 million.

Given that the growth rate is coming down to a level more in line with InMode’s expected future EBITDA CAGR (~39.5% from FY2019 to FY2023, per FactSet), we will leave our multiple unchanged at 30x, in line with InMode’s forward valuation multiple.

Using this FY2022 adjusted EBITDA, we generate an expected enterprise value (based on a 30x multiple) of $7.65 billion, up from our prior estimate of $5.15 billion. Adding this updated figure to our Bausch + Lomb and Bausch Pharma targets of $21.1 billion and $6 billion, respectively, we get a combined SOTP-based enterprise value (market cap + net debt) of $34.75 billion. Subtract out the ~$21.9 billion of net debt and we get to an equity value ~$12.85 billion, up from our previous combined estimate of $10.4 billion or ~$36 per share.

The CNBC Investing Club is now the official home to my Charitable Trust. It’s the place where you can see every move we make for the portfolio and get my market insight before anyone else. The Charitable Trust and my writings are no longer affiliated with Action Alerts Plus in any way.

As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. See here for the investing disclaimer.

(Jim Cramer’s Charitable Trust is long BHC.)

ShareTweetPin

Related Posts

The second-half is ‘not looking good’: Strategists on how to weather the market storm

by
July 5, 2022
0

A trader works on the floor of the New York Stock Exchange (NYSE), June 27, 2022. Brendan McDermid | Reuters...

Tesla Pauses Plants After Ending Shaky Quarter With a Production Milestone

by
July 5, 2022
0

Bloomberg US Recession Isn’t Goldman’s Base Case, Macro Strategist Says (Bloomberg) -- The base-case expectation isn’t for a recession in...

South Korea stocks lead broad gains in Asia; Reserve Bank of Australia hikes rates as expected

by
July 5, 2022
0

SINGAPORE -- Shares in the Asia-Pacific mostly traded higher as investors look ahead to the Reserve Bank of Australia's rate...

Stock futures rise after another losing week on Wall Street

by
July 5, 2022
0

Traders on the floor of the NYSE, July 1, 2022. Source: NYSE Stock futures inched higher in overnight trading after...

European stocks head for higher open as global markets look for gains after rout

by
July 5, 2022
0

LONDON -- European stocks are expected to open higher on Tuesday as global markets look to cement gains after a...

Next Post

New products put Apple on track for $4 trillion valuation

23 dividend stocks that can pass this strict quality screen

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Crocs sees fourth-quarter sales up 42%, CEO Andrew Rees says 2021 was ‘exceptional year’

    0 shares
    Share 0 Tweet 0
  • Buying a car from the factory sounds expensive, but it can actually save you money. Here’s how to do it.

    0 shares
    Share 0 Tweet 0
  • Roth TSP vs. Roth IRA: How Do They Compare?

    0 shares
    Share 0 Tweet 0
  • The states that won’t tax military retirement in 2022

    0 shares
    Share 0 Tweet 0
  • Allbirds stock has plunged 50% in two months, now one top analyst says buy it

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.stockmarket-cafe.com
No Result
View All Result
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy

All rights reserved by www.stockmarket-cafe.com